Prioritizing the patient – The discovery of lorlatinib, a macrocyclic ALK inhibitor for the treatment of resistant and metastatic NSCLC
Abstract: Primary and secondary mutations in anaplastic lymphoma kinase (ALK) are oncogenic. Insights into ALK acquired resistance were used to define a drug design strategy that led to the discovery of lorlatinib (Lorbrena; PF-06463922), a novel ATP-competitive macrocyclic inhibitor of ALK and ROS1 kinases. Structure based drug design, lipophilic efficiency and physicochemical property-based optimization provided […]